Is Mounjaro Approved in the UK — and What Does That Actually Mean?

Step 1: The MHRA's marketing authorisation, what it covers

Marketing authorisation is the foundational step. The MHRA reviewed the full clinical dossier for tirzepatide and granted Mounjaro a UK licence for weight management in adults with a BMI of 30 or above, or a BMI of 27 or above when at least one weight-related condition (such as high blood pressure, high cholesterol, type 2 diabetes, or obstructive sleep apnoea) is also present. That licence is the legal basis on which any UK prescriber can issue a prescription for the medicine.

Mounjaro is also licensed for type 2 diabetes, which is an entirely separate indication with its own clinical criteria. If you've arrived here because you've heard tirzepatide described as a diabetes drug, that's the reason, it's been authorised for both conditions, though the weight-management licence applies here. A detailed breakdown of the tirzepatide approval timeline covers how the two licences developed in parallel.

The Black Triangle (▼) designation on Mounjaro's packaging sometimes prompts questions. It simply means the MHRA wants additional post-market data collected while the medicine is in wider use, a standard condition for newer medicines and one that applies to many treatments on UK shelves. The NHS medicines information page for tirzepatide explains the Black Triangle status in plain language.

Step 2: What NICE TA1026 added, and how NHS access is being phased in

MHRA authorisation means a medicine is legal to prescribe. A NICE Technology Appraisal adds the NHS funding recommendation. NICE published TA1026 in December 2024, recommending tirzepatide for NHS use in England, and NHS England began the phased rollout from mid-2025.

The NHS eligibility criteria are deliberately narrow at launch. The first cohort, active from June 2025, covers adults with a BMI of 40 or above who also have four or more of five specified conditions: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, or type 2 diabetes. A second cohort, covering BMI 35 to 39.9 with four or more of those conditions, was activated in June 2026. Further cohorts extending access to lower BMI thresholds are planned through 2027. Throughout, ethnic-background adjustments apply, thresholds are 2.5 kg/m² lower for South Asian, Chinese, Middle Eastern, Black African, or African-Caribbean backgrounds, in line with NICE TA1026's recommendations.

If you want to understand exactly where NHS access stands right now, this page on Mounjaro's weight-loss approval status sets it out in full. The honest picture is that NHS eligibility remains restricted to people with higher BMIs and multiple comorbidities for the time being.

Step 3: Private prescription as the alternative route

Most people reading this are probably weighing up their options after finding that NHS access either doesn't apply to them yet or involves a long wait. That's a reasonable position to be in, and a private prescription route through a regulated pharmacy is entirely legal and widely used for licensed medicines.

The key difference with private access is who sets the eligibility criteria: the prescriber follows the licensed indications from the MHRA authorisation, rather than the NHS's narrower phased thresholds. An adult with a BMI of 30 or above, for instance, can be considered for treatment under the licence even though NHS criteria currently require higher BMIs and multiple comorbidities.

Private pricing is worth understanding before you commit. For context on what the market looks like following Eli Lilly's price changes in late 2025, the Mounjaro price comparison page runs through what typical private costs include and what headline prices sometimes leave out. One transparent price that covers consultation, prescription, and delivery is the right frame for comparison, not the lowest number you can find.

Whatever route you're considering, the clinical process doesn't change. Mounjaro is a prescription-only medicine. A prescriber assesses whether it's suitable for you specifically. That step cannot be skipped, and any offer that implies otherwise is a red flag worth taking seriously. The MHRA has warned publicly about counterfeit weight-loss pens sold online, and the consequences of buying from unverified sources range from ineffective to dangerous.

Step 4: Approval status for specific situations, sleep apnoea, age, and other conditions

A common follow-up once people know the drug is approved: is it approved for my situation? The licensed indications cover weight management in adults, which means the under-18 licence question has a clear answer, Mounjaro is not licensed for anyone under 18 in the UK. There are no approved paediatric data, and a prescriber cannot legally issue a prescription for a minor. More detail on the age criteria is covered on the Mounjaro age approval page.

Sleep apnoea is a different question. The MHRA licence already recognises obstructive sleep apnoea as one of the weight-related conditions that can lower the BMI threshold for eligibility. Whether tirzepatide may eventually hold a specific sleep apnoea indication of its own is a question worth tracking. The page on Mounjaro's potential sleep apnoea approval sets out what trial data currently exists and where the regulatory position stands. Our broader overview of tirzepatide covers approved indications side by side for anyone who wants the full picture in one place.

If you're ready to find out whether you're suitable for treatment through a private prescription, speaking to a prescriber is the straightforward next step. At nume, every consultation is reviewed by a GPhC-registered prescriber (a real clinician, not software) and the process is handled the same day for orders placed by 12pm.

You can speak to our prescribers through a free consultation, with no obligation until a prescription is issued.